In silico Molecular Docking and Scrutinizing Druglike Properties of Selected Phytoconstituents Against TAK1, Xanthin Oxidase, and IL-1 β Targets in Gouty Arthritis

Common manifestation of gout is deposition of monosodium urate crystals in joints followed by cytokinine-induced inflammatory responses. Xanthin Oxidase (PDB ID: 3NVY) and proinflammatory cytokinines, eg., TAK1 (PDB ID: 7NTH) and IL-1 β (PDB ID: 5R8Q) are vastly accountable for the severity of the disease. Inhibition of these targets with phytoconstituents would be preferable option in the treatment of gout patients. In the present study, in silico molecular docking analysis of Orientin, Vitexin, Apigenin, and Harman were performed using Glide XP, Schrodinger 2017_2, with above drug targets to investigate docking score, binding free energies and druggability. The results revealed a docking score and binding energy in the range of -11.862 kcal/mol to -3.130 kcal/ mol and -53.282 kcal/mol to -32.346 kcal/mol respectively. Except Harman all the compounds have considerable docking score and binding energies, which typically indicate that they have the optimum interaction with the binding sites. ADME/T analysis performed using QikProp program of Schrödinger 2017-2 and the SwissADME online server indicated that the Vitexin and Apigenin have the physiochemical properties to be developed as drugs. These studies can be used to develop alternate therapeutic options for the treatment of gout.